Diffusion Pharmaceuticals, Inc. (DFFN)
| Market Cap | 52.48M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.92M |
| Shares Out | 101.90M |
| EPS (ttm) | -0.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 409,650 |
| Open | 0.515 |
| Previous Close | 0.515 |
| Day's Range | 0.500 - 0.519 |
| 52-Week Range | 0.464 - 1.850 |
| Beta | 1.56 |
| Analysts | Hold |
| Price Target | 2.00 (+297.1%) |
| Est. Earnings Date | Nov 11, 2021 |
About DFFN
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company is also developing DFN-529, a phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway inhibitor. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for DFFN stock is "Hold" and the 12-month stock price forecast is 2.00.
News
Diffusion Pharmaceuticals Issues Letter to Shareholders
CHARLOTTESVILLE, Va., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies ...
Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference
Conference to Take Place Virtually, September 13-15, 2021 Conference to Take Place Virtually, September 13-15, 2021
Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA's Pulmonology, Allergy, and Critical ...
Phase 2 DLCO Trial in Interstitial Lung Disease Expected to Begin in Q4 Under New IND
Diffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business Update
CHARLOTTESVILLE, Va., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies t...
7 Trending Penny Stocks That You Need to Know About in July 2021
Are these trending penny stocks worth adding to your watchlist? The post 7 Trending Penny Stocks That You Need to Know About in July 2021 appeared first on Penny Stocks to Buy, Picks, News and Informati...
Diffusion Pharma's TSC Shows Encouraging Effects On Oxygenation
Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) has announced topline results from the Phase 1 trial of its lead product candidate, trans sodium crocetinate (TSC). In the trial, transcutaneous oxygen monit...
Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial
Trial Dosed Healthy Volunteers with Trans Sodium Crocetinate Trial Dosed Healthy Volunteers with Trans Sodium Crocetinate
Diffusion Pharmaceuticals to Webcast Live at Life Sciences Investor Forum
Presentation Scheduled for June 24, 2021 at 11:30 a.m., EDT Presentation Scheduled for June 24, 2021 at 11:30 a.m., EDT
Diffusion Pharmaceuticals Reminds Stockholders to Vote Shares In Advance of Annual Meeting
Annual Meeting Scheduled for June 25, 2021, at 1 p.m. EDT Annual Meeting Scheduled for June 25, 2021, at 1 p.m. EDT
Best Penny Stocks Today? 4 Small-Cap Stocks To Watch Under $1 In June
Hot Penny Stocks Under $1 To Watch This Month The post Best Penny Stocks Today? 4 Small-Cap Stocks To Watch Under $1 In June appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...
Diffusion Pharma's Trans Sodium Crocetinate Associated With Improved Outcomes In COVID-19 Patients
Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) has announced final results from the Phase 1b study evaluating trans sodium crocetinate (TSC) in hospitalized COVID-19 patients. Data from the open-label stu...
Diffusion Pharmaceuticals Reports Final Results from Its Phase 1b Study of Trans Sodium Crocetinate in Hospitalized C...
CHARLOTTESVILLE, Va., May 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies th...
Diffusion Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
CHARLOTTESVILLE, Va., May 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies th...
Top Biotech Penny Stocks on Reddit? Check These 3 Out
Biotech penny stocks are back in focus; should these 3 be on your watchlist? The post Top Biotech Penny Stocks on Reddit?
Diffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM Study
CHARLOTTESVILLE, Va., March 25, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies ...
Diffusion Pharmaceuticals Reports 2020 Financial Results and Provides Business Update
CHARLOTTESVILLE, Va., March 17, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies ...
Diffusion Pharmaceuticals, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference
CHARLOTTESVILLE, Va., March 04, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies ...
Diffusion Pharmaceuticals Announces Closing of $30 Million Bought Deal Offering of Common Stock
CHARLOTTESVILLE, Va., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies t...
Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients
No Dose Limiting Toxicities or Serious Adverse Events Observed in Dosing Regimen Previously Untested in Clinical Trial Setting No Dose Limiting Toxicities or Serious Adverse Events Observed in Dosing Re...
Diffusion Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $30 Million
CHARLOTTESVILLE, Va., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company developing no...
Diffusion Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock
CHARLOTTESVILLE, Va., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company developing no...
Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference
CHARLOTTESVILLE, Va., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that the Company is participating in the H.C. Wainwr...
Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates
Initiated and Advanced C linical Trial Evaluating Lead Product Candidate in COVID-19 Patients
Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer
CHARLOTTESVILLE, Va., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced the appointment of Christopher D. Galloway, M.D. to ...